AKSO has established a pathway-driven, innovative, and integrated portfolio of programs focusing on leveraging the immune system and critical components of the tissue microenvironment, to target cancer, autoimmune and fibrotic diseases.

AKSO’s R&D Paradigm:

• Target specific disease-driven biological pathways which ultimately supports the development of biomarker-based clinical studies.
• Therapeutic candidates are engineered through our unique DEEP platform technology to achieve optimal binding affinities to targets of interest.